Prolastin-C

Generic name: alpha-1-proteinase inhibitor (human)

Used for: Emphysema from inherited alpha-1 antitrypsin deficiency

How do you pay?

How to pay the least

Ask for the cash price

Prolastin-C

Prolastin-C is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.

  1. Ask your pharmacy for Prolastin-C’s cash price, and one or two other pharmacies too.

Compare every option

Question
Brand nameProlastin-C
Authorized genericalpha-1-proteinase inhibitor (human)
Regular genericalpha-1-proteinase inhibitor (human)
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Prolastin-C?
The original
–
–

Brand nameNo maker’s card

We didn’t find a savings card or cash price from Prolastin-C’s maker. Ask the pharmacy for Prolastin-C’s cash price. With insurance, ask what your plan charges.

Authorized genericNot sold

There isn’t one. An authorized generic is Prolastin-C itself, from the same company, sold without the brand name, and usually for less. For now Prolastin-C is the only choice; ask the pharmacy for its cash price, or your plan what it charges.

Regular genericNot sold

Prolastin-C is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, ask the pharmacy for Prolastin-C’s cash price, or your plan what it charges.

What it’s used for

What the FDA label says

PROLASTIN-C is an Alpha1-Proteinase Inhibitor (Human) (Alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of Alpha1-PI (alpha1-antitrypsin deficiency).

PROLASTIN-C increases antigenic and functional (anti-neutrophil elastase capacity, ANEC) serum levels and antigenic lung epithelial lining fluid levels of Alpha1-PI.

Limitations of Use:

  • The effect of augmentation therapy with any Alpha1-PI, including PROLASTIN-C, on pulmonary exacerbations and on the progression of emphysema in Alpha1-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trials.
  • Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C are not available.
  • PROLASTIN-C is not indicated as therapy for lung disease in patients in whom severe Alpha1-PI deficiency has not been established.

Source: the FDA label for Prolastin-C (GRIFOLS USA, LLC), February 25, 2022. Full label on DailyMed 

Good to know

Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/prolastin-c/